Pharmacological approaches to improving cognitive function in down syndrome: Current status and considerations

Drug Design, Development and Therapy

Volumn 9, Issue , 2014, Pages 103-125

  Gardiner, Katheleen J ^a  

^a University of Colorado Denver and Children s Hospital Colorado   (United States)

Author keywords

Clinical trials; Hsa21; Pharmacotherapy; Ts65Dn

Indexed keywords

ALPHA TOCOPHEROL; BENZYL[3 [[1 (3,4 DICHLOROPHENYL)ETHYL]AMINO] 2 HYDROXYPROPYL]PHOSPHINIC ACID; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINE; CHOLINESTERASE INHIBITOR; DONEPEZIL; EPIGALLOCATECHIN GALLATE; ESTROGEN; ETHOSUXIMIDE; FLUOXETINE; FORMOTEROL; GABAPENTIN; GALANTAMINE; GAMMA SECRETASE INHIBITOR; LITHIUM; MELATONIN; MEMANTINE; MINOCYCLINE; NEUROPROTECTIVE AGENT; NORADRENALIN DERIVATIVE; PENTETRAZOLE; PHYSOSTIGMINE; PICROTOXIN; PIRACETAM; PROTEIN INHIBITOR; RO 256981; SGS 111; SONIC HEDGEHOG AGONIST; UNCLASSIFIED DRUG; UNINDEXED DRUG; XAMOTEROL;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; COGNITION; DOWN SYNDROME; DRUG ACTIVITY; DRUG DESIGN; DRUG EFFICACY; GENETIC ASSOCIATION; GENETIC CONSERVATION; HUMAN; INTELLECTUAL IMPAIRMENT; LONG TERM DEPRESSION; LONG TERM POTENTIATION; METHYLATION; NERVOUS SYSTEM DEVELOPMENT; NEUROPROTECTION; NONHUMAN; PHENOTYPE; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; REVIEW; SUMOYLATION; ANIMAL; COGNITION DISORDERS; GENETICS;

ANIMALS; COGNITION DISORDERS; DOWN SYNDROME; HUMANS; NEUROPROTECTIVE AGENTS;

EID: 84919627277     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S51476     Document Type: Review

References (164)

1. Lott IT. Neurological phenotypes for Down syndrome across the life span. Prog Brain Res. 2012;197:101–121.
2. Irving C, Basu A, Richmond S, Burn J, Wren C. Twenty-year trends in prevalence and survival of Down syndrome. Eur J Hum Genet. 2008;16(11):1336–1340.
3. CDC, Centers for Disease Control and Prevention. Improved national prevalence for 18 major birth defects. MMWR. 2006;54:6–12.
4. Chapman RS, Hesketh LJ. Behavioral phenotype of individuals with Down syndrome. Ment Retard Dev Disabil Res Rev. 2000;6(2):84–95.
5. Silverman W. Down syndrome: cognitive phenotype. Ment Retard Dev Disabil Res Rev. 2007;13(3):228–236.
6. Wiseman FK, Alford KA, Tybulewicz VL, Fisher EM. Down syndrome – recent progress and future prospects. Hum Mol Genet. 2009; 18(R1):R75–R83.
7. Sturgeon X, Gardiner KJ. Transcript catalogs of human chromosome 21 and orthologous chimpanzee and mouse regions. Mamm Genome. 2011;22(5–6):261–271.
8. Vilardell M, Rasche A, Thormann A, et al. Meta-analysis of heterogeneous Down Syndrome data reveals consistent genome-wide dosage effects related to neurological processes. BMC Genomics. 2011; 12:229.
9. Sturgeon X, Le T, Ahmed MM, Gardiner KJ. Pathways to cognitive defcits in Down syndrome. Prog Brain Res. 2012;197:73–100.
10. Rueda N, Flórez J, Martínez-Cué C. Mouse models of Down syndrome as a tool to unravel the causes of mental disabilities. Neural Plast. 2012;2012:584071.
11. Das I, Reeves RH. The use of mouse models to understand and improve cognitive defcits in Down syndrome. Dis Model Mech. 2011; 4(5):596–606.
12. Liu C, Belichenko PV, Zhang L, et al. Mouse models for Down syndrome-associated developmental cognitive disabilities. Dev Neurosci. 2011;33(5):404–413.
13. Davisson MT, Schmidt C, Reeves RH, et al. Segmental trisomy as a mouse model for Down syndrome. Prog Clin Biol Res. 1993;384:117–133.
14. Reeves RH, Irving NG, Moran TH, et al. A mouse model for Down syndrome exhibits learning and behaviour defcits. Nat Genet. 1995;11(2): 177–184.
15. Duchon A, Raveau M, Chevalier C, Nalesso V, Sharp AJ, Herault Y. Identifcation of the translocation breakpoints in the Ts65Dn and Ts1Cje mouse lines: relevance for modeling Down syndrome. Mamm Genome. 2011;22(11–12):674–684.
16. Ahmed MM, Dhanasekaran AR, Tong S, et al. Protein profles in Tc1 mice implicate novel pathway perturbations in the Down syndrome brain. Hum Mol Genet. 2013;22(9):1709–1724.
17. Roubertoux PL, Carlier M. Mouse models of cognitive disabilities in trisomy 21 (Down syndrome). Am J Med Genet C Semin Med Genet. 2010;154C(4):400–416.
18. Li Z, Yu T, Morishima M, et al. Duplication of the entire 22.9 Mb human chromosome 21 syntenic region on mouse chromosome 16 causes cardiovascular and gastrointestinal abnormalities. Hum Mol Genet. 2007;16(11):1359–1366.
19. Yu T, Liu C, Belichenko P, et al. Effects of individual segmental trisomies of human chromosome 21 syntenic regions on hippocampal long-term potentiation and cognitive behaviors in mice. Brain Res. 2010;1366:162–171.
20. Yu T, Li Z, Jia Z, et al. A mouse model of Down syndrome trisomic for all human chromosome 21 syntenic regions. Hum Mol Genet. 2010; 19(14):2780–2791.
21. Das D, Phillips C, Hsieh W, Sumanth K, Dang V, Salehi A. Neurotransmitter-based strategies for the treatment of cognitive dysfunction in Down syndrome. Prog Neuropsychopharmacol Biol Psychiatry. 2014;54:140–148.
22. Stasko MR, Costa AC. Experimental parameters affecting the Morris water maze performance of a mouse model of Down syndrome. Behav Brain Res. 2004;154(1):1–17.
23. Granholm AC, Ford KA, Hyde LA, et al. Estrogen restores cognition and cholinergic phenotype in an animal model of Down syndrome. Physiol Behav. 2002;77(2–3):371–385.
24. Hunter CL, Bimonte-Nelson HA, Nelson M, Eckman CB, Granholm AC. Behavioral and neurobiological markers of Alzheimer’s disease in Ts65Dn mice: effects of estrogen. Neurobiol Aging. 2004;25(7):873–884.
25. Plane JM, Shen Y, Pleasure DE, Deng W. Prospects for minocycline neuroprotection. Arch Neurol. 2010;67(12):1442–1448.
26. Hunter CL, Bachman D, Granholm AC. Minocycline prevents cholinergic loss in a mouse model of Down’s syndrome. Ann Neurol. 2004; 56(5):675–688.
27. Siarey RJ, Carlson EJ, Epstein CJ, Balbo A, Rapoport SI, Galdzicki Z. Increased synaptic depression in the Ts65Dn mouse, a model for mental retardation in Down syndrome. Neuropharmacology. 1999;38(12):1917–1920.
28. Kleschevnikov AM, Belichenko PV, Villar AJ, Epstein CJ, Malenka RC, Mobley WC. Hippocampal long-term potentiation suppressed by increased inhibition in the Ts65Dn mouse, a genetic model of Down syndrome. J Neurosci. 2004;24(37):8153–8160.
29. Costa AC, Grybko MJ. Defcits in hippocampal CA1 LTP induced by TBS but not HFS in the Ts65Dn mouse: a model of Down syndrome. Neurosci Lett. 2005;382(3):317–322.
30. Fernandez F, Morishita W, Zuniga E, et al. Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome. Nat Neurosci. 2007;10(4):411–413.
31. Rueda N, Flórez J, Martínez-Cué C. Chronic pentylenetetrazole but not donepezil treatment rescues spatial cognition in Ts65Dn mice, a model for Down syndrome. Neurosci Lett. 2008;433(1):22–27.
32. Colas D, Chuluun B, Warrier D, et al. Short-term treatment with the GABAA receptor antagonist pentylenetetrazole produces a sustained pro-cognitive benefit in a mouse model of Down’s syndrome. Br J Pharmacol. 2013;169(5):963–973.
33. Arya R, Kabra M, Gulati S. Epilepsy in children with Down syndrome. Epileptic Disord. 2011;13(1):1–7.
34. Wetmore DZ, Garner CC. Emerging pharmacotherapies for neurodevelopmental disorders. J Dev Behav Pediatr. 2010;31(7): 564–581.
35. Deidda G, Bozarth IF, Cancedda L. Modulation of GABAergic transmission in development and neurodevelopmental disorders: investigating physiology and pathology to gain therapeutic perspectives. Front Cell Neurosci. 2014;8:119.
36. Collinson N, Kuenzi FM, Jarolimek W, et al. Enhanced learning and memory and altered GABAergic synaptic transmission in mice lacking the alpha 5 subunit of the GABAA receptor. J Neurosci. 2002; 22(13):5572–5580.
37. Sur C, Quirk K, Dewar D, Atack J, McKernan R. Rat and human hippocampal alpha5 subunit-containing gamma-aminobutyric AcidA receptors have alpha5 beta3 gamma2 pharmacological characteristics. Mol Pharmacol. 1998;54(5):928–933.
38. Howell O, Atack JR, Dewar D, McKernan RM, Sur C. Density and pharmacology of alpha5 subunit-containing GABA(A) receptors are preserved in hippocampus of Alzheimer’s disease patients. Neurosci-ence. 2000;98(4):669–675.
39. Braudeau J, Delatour B, Duchon A, et al. Specifc targeting of the GABA-A receptor α5 subtype by a selective inverse agonist restores cognitive deficits in Down syndrome mice. J Psychopharmacol. 2011;25(8):1030–1042.
40. Martínez-Cué C, Martínez P, Rueda N, et al. Reducing GABAA α5 receptor-mediated inhibition rescues functional and neuromorphological defcits in a mouse model of down syndrome. J Neurosci. 2013;33(9): 3953–3966.
41. Wang J, Liu S, Haditsch U, et al. Interaction of calcineurin and type-A GABA receptor gamma 2 subunits produces long-term depression at CA1 inhibitory synapses. J Neurosci. 2003;23(3):826–836.
42. Lipton SA. Pathologically-activated therapeutics for neuroprotection: mechanism of NMDA receptor block by memantine and S-nitrosylation. Curr Drug Targets. 2007;8(5):621–632.
43. Lieberman DN, Mody I. Regulation of NMDA channel function by endogenous Ca(2+)-dependent phosphatase. Nature. 1994; 369(6477):235–239.
44. Siddiqui A, Lacroix T, Stasko MR, Scott-McKean JJ, Costa AC, Gardiner KJ. Molecular responses of the Ts65Dn and Ts1Cje mouse models of Down syndrome to MK-801. Genes Brain Behav. 2008; 7(7):810–820.
45. Wu Y, Song W. Regulation of RCAN1 translation and its role in oxidative stress-induced apoptosis. FASEB J. 2013;27(1):208–221.
46. Jung MS, Park JH, Ryu YS, et al. Regulation of RCAN1 protein activity by Dyrk1A protein-mediated phosphorylation. J Biol Chem. 2011;286(46):40401–40412.
47. Costa AC, Scott-McKean JJ, Stasko MR. Acute injections of the NMDA receptor antagonist memantine rescue performance defcits of the Ts65Dn mouse model of Down syndrome on a fear conditioning test. Neuropsychopharmacology. 2008;33(7):1624–1632.
48. Rueda N, Llorens-Martín M, Flórez J, et al. Memantine normalizes several phenotypic features in the Ts65Dn mouse model of Down syndrome. J Alzheimers Dis. 2010;21(1):277–290.
49. Lockrow J, Boger H, Bimonte-Nelson H, Granholm AC. Effects of long-term memantine on memory and neuropathology in Ts65Dn mice, a model for Down syndrome. Behav Brain Res. 2011;221(2):610–622.
50. Scott-McKean JJ, Costa AC. Exaggerated NMDA mediated LTD in a mouse model of Down syndrome and pharmacological rescuing by memantine. Learn Mem. 2011;18(12):774–778.
51. Malberg JE, Eisch AJ, Nestler EJ, Duman RS. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci. 2000;20(24):9104–9110.
52. Clark S, Schwalbe J, Stasko MR, Yarowsky PJ, Costa AC. Fluoxetine rescues defcient neurogenesis in hippocampus of the Ts65Dn mouse model for Down syndrome. Exp Neurol. 2006;200(1):256–261.
53. Bianchi P, Ciani E, Guidi S, et al. Early pharmacotherapy restores neurogenesis and cognitive performance in the Ts65Dn mouse model for Down syndrome. J Neurosci. 2010;30(26):8769–8779.
54. Maya Vetencourt JF, Sale A, Viegi A, et al. The antidepressant fu-oxetine restores plasticity in the adult visual cortex. Science. 2008; 320(5874):385–388.
55. Choi HC, Kim YI, Song HK, Kim JE, Kim DS, Kang TC. Effects of selective serotonin reuptake inhibitors on GABAergic inhibition in the hippocampus of normal and pilocarpine induced epileptic rats. Brain Res. 2010;1357:131–141.
56. Caiati MD, Cherubini E. Fluoxetine impairs GABAergic signaling in hip-pocampal slices from neonatal rats. Front Cell Neurosci. 2013;7:63.
57. Heinen M, Hettich MM, Ryan DP, Schnell S, Paesler K, Ehninger D. Adult-onset fuoxetine treatment does not improve behavioral impairments and may have adverse effects on the Ts65Dn mouse model of Down syndrome. Neural Plast. 2012;2012:467251.
58. Begenisic T, Baroncelli L, Sansevero G, et al. Fluoxetine in adulthood normalizes GABA release and rescues hippocampal synaptic plasticity and spatial memory in a mouse model of Down syndrome. Neurobiol Dis. 2014;63:12–19.
59. Guidi S, Stagni F, Bianchi P, et al. Prenatal pharmacotherapy rescues brain development in a Down’s syndrome mouse model. Brain. 2014;137(Pt 2):380–401.
60. Chang Q, Gold PE. Age-related changes in memory and in acetylcholine functions in the hippocampus in the Ts65Dn mouse, a model of Down syndrome. Neurobiol Learn Mem. 2008;89(2):167–177.
61. de Souza FM, Busquet N, Blatner M, Maclean KN, Restrepo D. Galantamine improves olfactory learning in the Ts65Dn mouse model of Down syndrome. Sci Rep. 2011;1:137.
62. Nijjar RK, Murphy C. Olfactory impairment increases as a function of age in persons with Down syndrome. Neurobiol Aging. 2002;23(1):65–73.
63. Salehi A, Faizi M, Colas D, et al. Restoration of norepinephrine-modulated contextual memory in a mouse model of Down syndrome. Sci Transl Med. 2009;1(7):7ra17.
64. Faizi M, Bader PL, Tun C, et al. Comprehensive behavioral pheno-typing of Ts65Dn mouse model of Down syndrome: activation of β1-adrenergic receptor by xamoterol as a potential cognitive enhancer. Neurobiol Dis. 2011;43(2):397–413.
65. Lockrow J, Boger H, Gerhardt G, Aston-Jones G, Bachman D, Granholm AC. A noradrenergic lesion exacerbates neurodegeneration in a Down syndrome mouse model. J Alzheimers Dis. 2011;23(3):471–489.
66. Dang V, Medina B, Das D, et al. Formoterol, a long-acting β2 adrenergic agonist, improves cognitive function and promotes dendritic complexity in a mouse model of Down syndrome. Biol Psychiatry. 2014;75(3):179–188.
67. Pasquali L, Busceti CL, Fulceri F, Paparelli A, Fornai F. Intracellular pathways underlying the effects of lithium. Behav Pharmacol. 2010;21(5–6):473–492.
68. Wada A. Lithium and neuropsychiatric therapeutics: neuroplasticity via glycogen synthase kinase-3beta, beta-catenin, and neurotrophin cascades. J Pharmacol Sci. 2009;110(1):14–28.
69. Bianchi P, Ciani E, Contestabile A, Guidi S, Bartesaghi R. Lithium restores neurogenesis in the subventricular zone of the Ts65Dn mouse, a model for Down syndrome. Brain Pathol. 2010;20(1):106–118.
70. Contestabile A, Greco B, Ghezzi D, Tucci V, Benfenati F, Gasparini L. Lithium rescues synaptic plasticity and memory in Down syndrome mice. J Clin Invest. 2013;123(1):348–361.
71. Trazzi S, Fuchs C, De Franceschi M, Mitrugno VM, Bartesaghi R, Ciani E. APP-dependent alteration of GSK3β activity impairs neuro-genesis in the Ts65Dn mouse model of Down syndrome. Neurobiol Dis. 2014;67:24–36.
72. Singh M, Jadhav HR. Melatonin: functions and ligands. Drug Discov Today. 2014;19(9):1410–1418.
73. Wade AG, Farmer M, Harari G, et al. Add-on prolonged-release mela-tonin for cognitive function and sleep in mild to moderate Alzheimer’s disease: a 6-month, randomized, placebo-controlled, multicenter trial. Clin Interv Aging. 2014;9:947–961.
74. Corrales A, Martínez P, García S, et al. Long-term oral administration of melatonin improves spatial learning and memory and protects against cholinergic degeneration in middle-aged Ts65Dn mice, a model of Down syndrome. J Pineal Res. 2013;54(3):346–358.
75. Corrales A, Vidal R, García S, et al. Chronic melatonin treatment rescues electrophysiological and neuromorphological defcits in a mouse model of Down syndrome. J Pineal Res. 2014;56(1):51–61.
76. Roper RJ, Baxter LL, Saran NG, Klinedinst DK, Beachy PA, Reeves RH. Defective cerebellar response to mitogenic Hedgehog signaling in Down [corrected] syndrome mice. Proc Natl Acad Sci U S A. 2006;103(5):1452–1456.
77. Das I, Park JM, Shin JH, et al. Hedgehog agonist therapy corrects structural and cognitive defcits in a Down syndrome mouse model. Sci Transl Med. 2013;5(201):201ra120.
78. Bain J, McLauchlan H, Elliott M, Cohen P. The specifcities of protein kinase inhibitors: an update. Biochem J. 2003;371(Pt 1):199–204.
79. Hämmerle B, Elizalde C, Galceran J, Becker W, Tejedor FJ. The MNB/DYRK1A protein kinase: neurobiological functions and Down syndrome implications. J Neural Transm Suppl. 2003;(67):129–137.
80. Park J, Song WJ, Chung KC. Function and regulation of Dyrk1A: towards understanding Down syndrome. Cell Mol Life Sci. 2009;66(20): 3235–3240.
81. Becker W, Sippl W. Activation, regulation, and inhibition of DYRK1A. FEBS J. 2011;278(2):246–256.
82. Tejedor FJ, Hämmerle B. MNB/DYRK1A as a multiple regulator of neuronal development. FEBS J. 2011;278(2):223–235.
83. Xie W, Ramakrishna N, Wieraszko A, Hwang YW. Promotion of neuronal plasticity by (-)-epigallocatechin-3-gallate. Neurochem Res. 2008;33(5):776–783.
84. De la Torre R, De Sola S, Pons M, et al. Epigallocatechin-3-gallate, a DYRK1A inhibitor, rescues cognitive defcits in Down syndrome mouse models and in humans. Mol Nutr Food Res. 2014;58(2): 278–288.
85. Ryoo SR, Cho HJ, Lee HW, et al. Dual-specificity tyrosine(Y)-phosphorylation regulated kinase 1A-mediated phosphorylation of amyloid precursor protein: evidence for a functional link between Down syndrome and Alzheimer’s disease. J Neurochem. 2008;104(5)1333–1344.
86. Adayev T, Chen-Hwang MC, Murakami N, Wang R, Hwang YW. MNB/ DYRK1A phosphorylation regulates the interactions of synaptojanin 1 with endocytic accessory proteins. Biochem Biophys Res Commun. 2006;351(4):1060–1065.
87. Shimokawa T, Rahman MF, Tostar U, et al. RNA editing of the GLI1 transcription factor modulates the output of Hedgehog signaling. RNA Biol. 2013;10(2):321–333.
88. Morita K, Lo Celso C, Spencer-Dene B, Zouboulis CC, Watt FM. HAN11 binds mDia1 and controls GLI1 transcriptional activity. J Dermatol Sci. 2006;44(1):11–20.
89. Singh BN, Shankar S, Srivastava RK. Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications. Biochem Pharmacol. 2011;82(12):1807–1821.
90. Patra SK, Rizzi F, Silva A, Rugina DO, Bettuzzi S. Molecular targets of (-)-epigallocatechin-3-gallate (EGCG): specifcity and interaction with membrane lipid rafts. J Physiol Pharmacol. 2008;59 Suppl 9: 217–235.
91. Coskun PE, Busciglio J. Oxidative Stress and Mitochondrial Dysfunction in Down’s Syndrome: Relevance to Aging and Dementia. Curr Gerontol Geriatr Res. 2012;2012:383170.
92. Busciglio J, Yankner BA. Apoptosis and increased generation of reactive oxygen species in Down’s syndrome neurons in vitro. Nature. 1995;378(6559):776–779.
93. Lockrow J, Prakasam A, Huang P, Bimonte-Nelson H, Sambamurti K, Granholm AC. Cholinergic degeneration and memory loss delayed by vitamin E in a Down syndrome mouse model. Exp Neurol. 2009; 216(2):278–289.
94. Shichiri M, Yoshida Y, Ishida N, et al. α-Tocopherol suppresses lipid peroxidation and behavioral and cognitive impairments in the Ts65Dn mouse model of Down syndrome. Free Radic Biol Med. 2011; 50(12):1801–1811.
95. Netzer WJ, Powell C, Nong Y, et al. Lowering beta-amyloid levels rescues learning and memory in a Down syndrome mouse model. PLoS One. 2010;5(6):e10943.
96. Shiryaev N, Pikman R, Giladi E, Gozes I. Protection against tauopathy by the drug candidates NAP (davunetide) and D-SAL: biochemical, cellular and behavioral aspects. Curr Pharm Des. 2011;17(25):2603–2612.
97. Incerti M, Toso L, Vink J, et al. Prevention of learning defcit in a Down syndrome model. Obstet Gynecol. 2011;117(2 Pt 1):354–361.
98. Incerti M, Horowitz K, Roberson R, et al. Prenatal treatment prevents learning defcit in Down syndrome model. PLoS One. 2012; 7(11):e50724.
99. Chohan MO, Li B, Blanchard J, et al. Enhancement of dentate gyrus neurogenesis, dendritic and synaptic plasticity and memory by a neurotrophic peptide. Neurobiol Aging. 2011;32(8):1420–1434.
100. Blanchard J, Bolognin S, Chohan MO, Rabe A, Iqbal K, Grundke-Iqbal I. Rescue of synaptic failure and alleviation of learning and memory impairments in a trisomic mouse model of down syndrome. J Neuropathol Exp Neurol. 2011;70(12):1070–1079.
101. McCann JC, Hudes M, Ames BN. An overview of evidence for a causal relationship between dietary availability of choline during development and cognitive function in offspring. Neurosci Biobehav Rev. 2006;30(5):696–712.
102. Glenn MJ, Gibson EM, Kirby ED, Mellott TJ, Blusztajn JK, Williams CL. Prenatal choline availability modulates hippocampal neurogenesis and neurogenic responses to enriching experiences in adult female rats. Eur J Neurosci. 2007;25(8):2473–2482.
103. Moon J, Chen M, Gandhy SU, et al. Perinatal choline supplementation improves cognitive functioning and emotion regulation in the Ts65Dn mouse model of Down syndrome. Behav Neurosci. 2010; 124(3):346–361.
104. Velazquez R, Ash JA, Powers BE, et al. Maternal choline supplementation improves spatial learning and adult hippocampal neurogenesis in the Ts65Dn mouse model of Down syndrome. Neurobiol Dis. 2013;58:92–101.
105. Ash JA, Velazquez R, Kelley CM, et al. Maternal choline supplementation improves spatial mapping and increases basal forebrain cholinergic neuron number and size in aged Ts65Dn mice. Neurobiol Dis. 2014;70:32–42.
106. Cramer NP, Best TK, Stoffel M, Siarey RJ, Galdzicki Z. GABAB-GIRK2-mediated signaling in Down syndrome. Adv Pharmacol. 2010;58:397–426.
107. Best TK, Cramer NP, Chakrabarti L, Haydar TF, Galdzicki Z. Dysfunctional hippocampal inhibition in the Ts65Dn mouse model of Down syndrome. Exp Neurol. 2012;233(2):749–757.
108. Best TK, Siarey RJ, Galdzicki Z. Ts65Dn, a mouse model of Down syndrome, exhibits increased GABAB-induced potassium current. J Neurophysiol. 2007;97(1):892–900.
109. Kleschevnikov AM, Belichenko PV, Faizi M, et al. Defcits in cognition and synaptic plasticity in a mouse model of Down syndrome ameliorated by GABAB receptor antagonists. J Neurosci. 2012; 32(27):9217–9227.
110. Heller JH, Spiridigliozzi GA, Doraiswamy PM, Sullivan JA, Crissman BG, Kishnani PS. Donepezil effects on language in children with Down syndrome: results of the frst 22-week pilot clinical trial. Am J Med Genet A. 2004;130A(3):325–326.
111. Yuede CM, Dong H, Csernansky JG. Anti-dementia drugs and hippocampal-dependent memory in rodents. Behav Pharmacol. 2007; 18(5–6):347–363.
112. Malykh AG, Sadaie MR. Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders. Drugs. 2010;70(3):287–312.
113. Moran TH, Capone GT, Knipp S, Davisson MT, Reeves RH, Gearhart JD. The effects of piracetam on cognitive performance in a mouse model of Down’s syndrome. Physiol Behav. 2002;77(2–3):403–409.
114. Rueda N, Flórez J, Martínez-Cué C. Effects of chronic administration of SGS-111 during adulthood and during the pre- and post-natal periods on the cognitive defcits of Ts65Dn mice, a model of Down syndrome. Behav Brain Res. 2008;188(2):355–367.
115. Pelsman A, Hoyo-Vadillo C, Gudasheva TA, Seredenin SB, Ostrovskaya RU, Busciglio J. GVS-111 prevents oxidative damage and apoptosis in normal and Down’s syndrome human cortical neurons. Int J Dev Neurosci. 2003;21(3):117–124.
116. Cooper A, Grigoryan G, Guy-David L, Tsoory MM, Chen A, Reuveny E. Trisomy of the G protein-coupled K+ channel gene, Kcnj6, affects reward mechanisms, cognitive functions, and synaptic plasticity in mice. Proc Natl Acad Sci U S A. 2012;109(7):2642–2647.
117. Vidal V, García S, Martínez P, et al. Lack of behavioral and cognitive effects of chronic ethosuximide and gabapentin treatment in the Ts65Dn mouse model of Down syndrome. Neuroscience. 2012;220:158–168.
118. Hanson JE, Weber M, Meilandt WJ, et al. GluN2B antagonism affects interneurons and leads to immediate and persistent changes in synaptic plasticity, oscillations, and behavior. Neuropsychopharmacology. 2013;38(7):1221–1233.
119. Paul CM, Magda G, Abel S. Spatial memory: Theoretical basis and comparative review on experimental methods in rodents. Behav Brain Res. 2009;203(2):151–164.
120. Hernández-Rabaza V, Llorens-Martín M, Velázquez-Sánchez C, et al. Inhibition of adult hippocampal neurogenesis disrupts contextual learning but spares spatial working memory, long-term conditional rule retention and spatial reversal. Neuroscience. 2009;159(1):59–68.
121. Alwan S, Friedman JM. Safety of selective serotonin reuptake inhibitors in pregnancy. CNS Drugs. 2009;23(6):493–509.
122. Cantor Sackett J, Weller RA, Weller EB. Selective serotonin reuptake inhibitor use during pregnancy and possible neonatal complications. Curr Psychiatry Rep. 2009;11(3):253–257.
123. Seeman P, Caruso C, Lasaga M. Memantine agonist action at dopamine D2High receptors. Synapse. 2008;62(2):149–153.
124. Nakaya K, Nakagawasai O, Arai Y, et al. Pharmacological characterizations of memantine-induced disruption of prepulse inhibition of the acoustic startle response in mice: involvement of dopamine D2 and 5-HT2A receptors. Behav Brain Res. 2011;218(1):165–173.
125. Rogóz Z, Skuza G, Maj J, Danysz W. Synergistic effect of uncom-petitive NMDA receptor antagonists and antidepressant drugs in the forced swimming test in rats. Neuropharmacology. 2002; 42(8):1024–1030.
126. Méndez P, Pazienti A, Szabó G, Bacci A. Direct alteration of a specifc inhibitory circuit of the hippocampus by antidepressants. J Neurosci. 2012;32(47):16616–16628.
127. Luscher B, Fuchs T, Kilpatrick CL. GABAA receptor traffcking-mediated plasticity of inhibitory synapses. Neuron. 2011;70(3): 385–409.
128. Berry-Kravis E, Hessl D, Abbeduto L, Reiss AL, Beckel-Mitchener A, Urv TK; Outcome Measures Working Groups. Outcome measures for clinical trials in fragile X syndrome. J Dev Behav Pediatr. 2013; 34(7):508–522.
129. Kishnani PS, Heller JH, Spiridigliozzi GA, et al. Donepezil for treatment of cognitive dysfunction in children with Down syndrome aged 10–17. Am J Med Genet A. 2010;152A(12):3028–3035.
130. Johnson N, Fahey C, Chicoine B, Chong G, Gitelman D. Effects of donepezil on cognitive functioning in Down syndrome. Am J Ment Retard. 2003;108(6):367–372.
131. Heller JH, Spiridigliozzi GA, Crissman BG, McKillop JA, Yamamoto H, Kishnani PS. Safety and effcacy of rivastigmine in adolescents with Down syndrome: long-term follow-up. J Child Adolesc Psychopharmacol. 2010;20(6):517–520.
132. Blehaut H, Mircher C, Ravel A, et al. Effect of leucovorin (folinic acid) on the developmental quotient of children with Down’s syndrome (trisomy 21) and infuence of thyroid status. PLoS One. 2010;5(1):e8394.
133. Park SW, Huang WH, Persaud SD, Wei LN. RIP140 in thyroid hormone-repression and chromatin remodeling of Crabp1 gene during adipocyte differentiation. Nucleic Acids Res. 2009;37(21): 7085–7094.
134. Lott IT, Doran E, Nguyen VQ, Tournay A, Head E, Gillen DL. Down syndrome and dementia: a randomized, controlled trial of antioxidant supplementation. Am J Med Genet A. 2011;155A(8):1939–1948.
135. Hanney M, Prasher V, Williams N, et al; MEADOWS trial researchers. Memantine for dementia in adults older than 40 years with Down’s syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trial. Lancet. 2012;379(9815):528–536.
136. Boada R, Hutaff-Lee C, Schrader A, et al. Antagonism of NMDA receptors as a potential treatment for Down syndrome: a pilot randomized controlled trial. Transl Psychiatry. 2012;2:e141.
137. Perrin S. Preclinical research: Make mouse studies work. Nature. 2014;507(7493):423–425.
138. Dekker AD, De Deyn PP, Rots MG. Epigenetics: the neglected key to minimize learning and memory defcits in Down syndrome. Neurosci Biobehav Rev. 2014;45:72–84.
139. Jones MJ, Farré P, McEwen LM, et al. Distinct DNA methylation patterns of cognitive impairment and trisomy 21 in Down syndrome. BMC Med Genomics. 2013;6:58.
140. Sanderson TM, Sher E. The role of phosphodiesterases in hippocampal synaptic plasticity. Neuropharmacology. 2013;74:86–95.
141. Kroker KS, Mathis C, Marti A, Cassel JC, Rosenbrock H, Dorner-Ciossek C. PDE9A inhibition rescues amyloid beta-induced deficits in synaptic plasticity and cognition. Neurobiol Aging. 2014;35(9):2072–2078.
142. Deininger MH, Fimmen BA, Thal DR, Schluesener HJ, Meyermann R. Aberrant neuronal and paracellular deposition of endostatin in brains of patients with Alzheimer’s disease. J Neurosci. 2002;22(24):10621–10626.
143. Hou Q, Ling L, Wang F, Xing S, Pei Z, Zeng J. Endostatin expression in neurons during the early stage of cerebral ischemia is associated with neuronal apoptotic cell death in adult hypertensive rat model of stroke. Brain Res. 2010;1311:182–188.
144. Al Ahmad A, Lee B, Stack J, et al. Endostatin binds nerve growth factor and thereby inhibits neurite outgrowth and neuronal migration in vitro. Brain Res. 2010;1360:28–39.
145. Wang T, Hauswirth AG, Tong A, Dickman DK, Davis GW. Endostatin is a trans-synaptic signal for homeostatic synaptic plasticity. Neuron. 2014;83(3):616–629.
146. Shi HS, Yin X, Song L, Guo QJ, Luo XH. Neuropeptide Trefoil factor 3 improves learning and retention of novel object recognition memory in mice. Behav Brain Res. 2012;227(1):265–269.
147. Morice E, Andreae LC, Cooke SF, et al. Preservation of long-term memory and synaptic plasticity despite short-term impairments in the Tc1 mouse model of Down syndrome. Learn Mem. 2008;15(7): 492–500.
148. Pereira PL, Magnol L, Sahún I, et al. A new mouse model for the trisomy of the Abcg1-U2af1 region reveals the complexity of the combinatorial genetic code of down syndrome. Hum Mol Genet. 2009; 18(24):4756–4769.
149. Yang DS, Stavrides P, Mohan PS, et al. Therapeutic effects of remediating autophagy failure in a mouse model of Alzheimer disease by enhancing lysosomal proteolysis. Autophagy. 2011;7(7):788–789.
150. Li Y, Wang H, Wang S, Quon D, Liu YW, Cordell B. Positive and negative regulation of APP amyloidogenesis by sumoylation. Proc Natl Acad Sci U S A. 2003;100(1):259–264.
151. Lu J, Esposito G, Scuderi C, et al. S100B and APP promote a gliocentric shift and impaired neurogenesis in Down syndrome neural progenitors. PLoS One. 2011;6(7):e22126.
152. Wilcock DM, Griffn WS. Down’s syndrome, neuroinfammation, and Alzheimer neuropathogenesis. J Neuroinfammation. 2013;10:84.
153. Block A, Dhanasekaran AR, Ahmed MD, Gardiner KJ. Abnormal protein profles in hippocampus of mouse models of Down syndrome: similarities with Alzheimers disease. J Alzheimers Dis Parkinsonism. 2014;4:138–149.
154. Nazıroğlu M, Çǧelik Ö, Özgül C, et al. Melatonin modulates wireless (2.45 GHz)-induced oxidative injury through TRPM2 and voltage gated Ca(2+) channels in brain and dorsal root ganglion in rat. Physiol Behav. 2012;105(3):683–692.
155. Xie YF, Belrose JC, Lei G, et al. Dependence of NMDA/GSK-3β mediated metaplasticity on TRPM2 channels at hippocampal CA3-CA1 synapses. Mol Brain. 2011;4:44.
156. Zhang L, Meng K, Jiang X, et al. Human chromosome 21 orthologous region on mouse chromosome 17 is a major determinant of Down syndrome-related developmental cognitive defcits. Hum Mol Genet. 2014; 23(3):578–589.
157. Worby CA, Simonson-Leff N, Clemens JC, Kruger RP, Muda M, Dixon JE. The sorting nexin, DSH3PX1, connects the axonal guidance receptor, Dscam, to the actin cytoskeleton. J Biol Chem. 2001; 276(45):41782–41789.
158. Shin N, Lee S, Ahn N, et al. Sorting nexin 9 interacts with dynamin 1 and N-WASP and coordinates synaptic vesicle endocytosis. J Biol Chem. 2007;282(39):28939–28950.
159. Duguay D, Bélanger-Nelson E, Mongrain V, Beben A, Khatchadourian A, Cermakian N. Dynein light chain Tctex-type 1 modulates orexin signaling through its interaction with orexin 1 receptor. PLoS One. 2011;6(10):e26430.
160. Salehi A, Delcroix JD, Belichenko PV, et al. Increased App expression in a mouse model of Down’s syndrome disrupts NGF transport and causes cholinergic neuron degeneration. Neuron. 2006;51(1):29–42.
161. Troca-Marín JA, Alves-Sampaio A, Montesinos ML. An increase in basal BDNF provokes hyperactivation of the Akt-mammalian target of rapamycin pathway and deregulation of local dendritic translation in a mouse model of Down’s syndrome. J Neurosci. 2011;31(26):9445–9455.
162. Ahmed MM, Sturgeon X, Ellison M, Davisson MT, Gardiner KJ. Loss of correlations among proteins in brains of the Ts65Dn mouse model of down syndrome. J Proteome Res. 2012;11(2):1251–1263.
163. Jaynes J, Ding X, Xu H, Wong WK, Ho CM. Application of fractional factorial designs to study drug combinations. Stat Med. 2013;32(2): 307–318.
164. Honda Y, Ding X, Mussano F, Wiberg A, Ho CM, Nishimura I. Guiding the osteogenic fate of mouse and human mesenchymal stem cells through feedback system control. Sci Rep. 2013;3:3420.